Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2–negative metastatic breast cancer

Clinical Cancer Research

Volumn 23, Issue 18, 2017, Pages 5358-5365

  Schott, Anne F ^a   Goldstein, Lori J ^b   Cristofanilli, Massimo ^c   Ruffini, Pier Adelchi ^d   McCanna, Susan ^d   Reuben, James M ^e   Perez, Raymond P ^f   Kato, Giraldo ^g   Wicha, Max ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Chemistry Section   (Italy)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^g Pinnacle Oncology Hematology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; REPARIXIN; TAXANE DERIVATIVE; 2-(4-ISOBUTYLPHENYL)PROPIONYLMETHANESULFONAMIDE; ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR1; ERBB2 PROTEIN, HUMAN; SULFONAMIDE; TUMOR MARKER;

ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BREAST CANCER STEM CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER STEM CELL; CLINICAL ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LIVER FUNCTION TEST; LIVER METASTASIS; MALE; MAXIMUM PLASMA CONCENTRATION; METASTATIC BREAST CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; STOMACH CANCER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; METABOLISM; METASTASIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 1 CLINICAL TRIAL; RETREATMENT; TREATMENT OUTCOME; TUMOR EMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PACLITAXEL; PILOT PROJECTS; RECEPTOR, ERBB-2; RECEPTORS, INTERLEUKIN-8A; RETREATMENT; SULFONAMIDES; TREATMENT OUTCOME;

EID: 85028555758     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-2748     Document Type: Article

References (33)

1. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339–44.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983–8.
3. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555–67.
4. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009; 69:1302–13.
5. Bhola NE, Balko JM, Dugger TC, Kuba MG, Sanchez V, Sanders M, et al. TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest 2013;123:1348–58.
6. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010;120:485–97.
7. Samanta D, Gilkes DM, Chaturvedi P, Xiang L, Semenza GL. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci U S A 2014;111:E5429–38.
8. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100:672–9.
9. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009;106: 13820–5.
10. Singh JK, Farnie G, Bundred NJ, Simoes BM, Shergill A, Landberg G, et al. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res 2013;19:643–56.
11. Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A 2004;101:11791–6.
12. Allegretti M, Bertini R, Cesta MC, Bizzarri C, Di Bitondo R, Di Cioccio V, et al. 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem 2005;48:4312–31.
13. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781–91.
14. Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, et al. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: adnagen adnatest breast-cancer select/detect versus veridex CellSearch system. Int J Cancer 2012; 130:1590–7.
15. Van der Auwera I, Peeters D, Benoy IH, Elst HJ, Van Laere SJ, Prove A, et al. Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer 2010;102:276–84.
16. Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, et al. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer 2012;130:808–16.
17. Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, et al. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther 2012;11:2526–34.
18. Reuben JM, Lee BN, Li C, Gao H, Broglio KR, Valero V, et al. Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. Breast J 2010;16:327–30.
19. Giordano A, Gao H, Cohen EN, Anfossi S, Khoury J, Hess K, et al. Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. Ann Oncol 2013;24:2515–21.
20. Campone M, Levy V, Bourbouloux E, Berton Rigaud D, Bootle D, Dutreix C, et al. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer 2009;100: 315–21.
21. Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187–92.
22. Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 2008;19:2012–19.
23. Citro A, Cantarelli E, Maffi P, Nano R, Melzi R, Mercalli A, et al. CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. J Clin Invest 2012;122:3647–51.
24. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666–76.
25. Carlson K, Ocean AJ. Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clin Breast Cancer 2011; 11:73–81.
26. Brandolini L, Benedetti E, Ruffini PA, Russo R, Cristiano L, Antonosante A, et al. CXCR1/2 pathways in paclitaxel-induced neuropathic pain. Oncotarget 2017;8:23188–201.
27. Kaiser J. The cancer stem cell gamble. Science 2015;347:226–9.
28. ClinicalTrials.gov. Pilot study to evaluate the safety and biological effects of orally administered reparixin in early breast cancer patients; 2013. Available from: http://clinicaltrials.gov/show/NCT01861054.
29. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002;87:21–7.
30. Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, et al. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res 2014;16:440.
31. Twelves C, Cortes J, Kaufman PA, Yelle L, Awada A, Binder TA, et al. "New" metastases are associated with a poorer prognosis than growth of preexisting metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Res 2015;17:150.
32. Brandolini L, Cristiano L, Fidoamore A, De Pizzol M, Di Giacomo E, Florio TM, et al. Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling. Oncotarget 2015;6:43375–94.
33. ClinicalTrials.gov. A double-blind study of paclitaxel in combination with reparixin or placebo for metastatic triple-negative breast cancer (FRIDA); 2015. Available from:http://clinicaltrials.gov/show/NCT02370238.